Arcutis Biotherapeutics (ARQT)
(Delayed Data from NSDQ)
$9.10 USD
-0.58 (-5.99%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $9.09 -0.01 (-0.11%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Balance Sheet
Fiscal Year End for Arcutis Biotherapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 273 | 411 | 389 | 286 | 101 |
Receivables | 26 | 8 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 13 | 8 | 0 | 0 | 0 |
Other Current Assets | 19 | 11 | 14 | 7 | 5 |
Total Current Assets | 330 | 437 | 403 | 293 | 106 |
Net Property & Equipment | 2 | 2 | 2 | 2 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 6 | 7 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 0 | 0 | 0 | 0 |
Total Assets | 341 | 449 | 408 | 298 | 107 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 12 | 9 | 7 | 7 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 34 | 28 | 26 | 15 | 4 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 47 | 38 | 33 | 23 | 5 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 202 | 198 | 72 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 166 |
Total Liabilities | 253 | 240 | 110 | 28 | 172 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,071 | 930 | 706 | 473 | 1 |
Retained Earnings | -982 | -720 | -408 | -202 | -66 |
Other Equity | 0 | -1 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 89 | 210 | 298 | 271 | -65 |
Total Liabilities & Shareholder's Equity | 341 | 449 | 408 | 298 | 107 |
Total Common Equity | 89 | 210 | 298 | 271 | -65 |
Shares Outstanding | 94.30 | 60.90 | 50.30 | 43.60 | NA |
Book Value Per Share | 0.94 | 3.44 | 5.92 | 6.21 | 0.00 |
Fiscal Year End for Arcutis Biotherapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 363 | 404 | 273 | 228 | 270 |
Receivables | 43 | 37 | 26 | 19 | 17 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 14 | 13 | 13 | 14 | 10 |
Other Current Assets | 14 | 13 | 19 | 20 | 12 |
Total Current Assets | 435 | 468 | 330 | 282 | 309 |
Net Property & Equipment | 1 | 1 | 2 | 2 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 6 | 6 | 6 | 7 | 7 |
Deposits & Other Assets | 1 | 1 | 1 | 1 | 1 |
Total Assets | 445 | 479 | 341 | 293 | 321 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 8 | 13 | 12 | 13 | 17 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 43 | 34 | 34 | 28 | 19 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 51 | 47 | 47 | 42 | 37 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 204 | 203 | 202 | 201 | 200 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 1 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 258 | 254 | 253 | 246 | 240 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,256 | 1,242 | 1,071 | 963 | 952 |
Retained Earnings | -1,070 | -1,017 | -982 | -916 | -871 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 186 | 225 | 89 | 47 | 81 |
Total Liabilities & Shareholder's Equity | 445 | 479 | 341 | 293 | 321 |
Total Common Equity | 186 | 225 | 89 | 47 | 81 |
Shares Outstanding | 115.70 | 115.50 | 94.30 | 61.80 | 61.40 |
Book Value Per Share | 1.61 | 1.95 | 0.94 | 0.76 | 1.31 |